Volume | 29,408 |
|
|||||
News | - | ||||||
Day High | 12.205 | Low High |
|||||
Day Low | 11.65 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Cidara Therapeutics Inc | CDTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
12.00 | 11.65 | 12.205 | 12.02 | 11.92 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
403 | 29,408 | US$ 11.96 | US$ 351,722 | - | 10.004 - 27.60 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:27:02 | 1 | US$ 11.85 | USD |
Cidara Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.09B | 90.43M | - | 63.91M | -22.93M | -0.25 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cidara Therapeutics News
Date | Time | Source | News Article |
---|---|---|---|
5/23/2024 | 15:59 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
5/20/2024 | 15:04 | Edgar (US Regulatory) | Form 8-K - Current report |
3/04/2024 | 15:22 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
2/23/2024 | 15:05 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
2/09/2024 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
12/22/2023 | 06:33 | Edgar (US Regulatory) | Form 8-K - Current report |
11/17/2023 | 12:22 | Edgar (US Regulatory) | Form 8-K - Current report |
11/16/2023 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
11/02/2023 | 15:08 | Edgar (US Regulatory) | Form 8-K - Current report |
11/02/2023 | 15:05 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
10/13/2023 | 09:36 | Edgar (US Regulatory) | Form 8-K - Current report |
9/21/2023 | 12:24 | Edgar (US Regulatory) | Form 8-K - Current report |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CDTX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 12.00 | 13.17 | 10.50 | 11.80 | 85,368 | 0.02 | 0.17% |
1 Month | 12.65 | 14.1206 | 10.50 | 12.33 | 68,523 | -0.63 | -4.98% |
3 Months | 14.236 | 24.40 | 10.004 | 16.11 | 636,590 | -2.22 | -15.57% |
6 Months | 14.178 | 24.40 | 10.004 | 15.53 | 653,142 | -2.16 | -15.22% |
1 Year | 27.00 | 27.60 | 10.004 | 17.86 | 588,645 | -14.98 | -55.48% |
3 Years | 40.60 | 47.80 | 8.00 | 24.37 | 812,475 | -28.58 | -70.39% |
5 Years | 38.40 | 89.00 | 8.00 | 31.41 | 647,474 | -26.38 | -68.70% |
Cidara Therapeutics Description
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. |